Rhythm Pharmaceuticals (RYTM) P/S ratio
Rhythm Pharmaceuticals (RYTM) trades at 39.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 36.7×. That is 39.7% higher than the 26.2× of fiscal 2024. Figures as of 18 Nov 2026, 02:34 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio today
- 39.9×
- P/S ratio, fiscal 2025
- 36.7×
- Change on fiscal 2024
- +39.7%
- Highest on record
- 156.9×fiscal 2021
- Lowest on record
- 26.2×fiscal 2024
- Fiscal years on record
- 52021–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Rhythm Pharmaceuticals P/S ratio, in more detail
Today's figure is 8.9% above the fiscal 2025 year-end.
Across the 5 fiscal year-ends on record (2021–2025), the highest was 156.9× in fiscal 2021 and the lowest 26.2× in fiscal 2024. Today's P/S ratio is higher than at 60% of the 5 fiscal year-ends on record; their median is 36.7×.
P/S ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Rhythm Pharmaceuticals P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 39.9× | — | $116.61 | — | |
| 2025 | 36.7× | 39.7% up | $107.04 | $2.92 | |
| 2024 | 26.2× | 23.4% down | $55.98 | $2.13 | |
| 2023 | 34.2× | 46.7% down | $45.97 | $1.34 | |
| 2022 | 64.2× | 59.1% down | $29.12 | $0.45 | |
| 2021 | 156.9× | — | $9.98 | $0.06 | |
| 2020 | — | — | $29.73 | — | |
| 2019 | — | — | $22.96 | — | |
| 2018 | — | — | $26.88 | — | |
| 2017 | — | — | $29.06 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
P/S ratio at health care companies of similar size
| Company | P/S ratio |
|---|---|
| Rhythm Pharmaceuticals RYTM | 42.6× |
| Alkermes ALKS | 5.2× |
| PACS Group PACS | 1.5× |
| Kiniksa Pharmaceuticals International KNSA | 11.0× |
| ImmunityBio IBRX | 58.8× |
| Cytokinetics CYTK | 81.7× |
Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.
Rhythm Pharmaceuticals, figure by figure
- Rhythm Pharmaceuticals market cap
- Rhythm Pharmaceuticals revenue
- Rhythm Pharmaceuticals earnings
- Rhythm Pharmaceuticals earnings per share (EPS)
- Rhythm Pharmaceuticals P/E ratio
- Rhythm Pharmaceuticals P/B ratio
- Rhythm Pharmaceuticals free cash flow
- Rhythm Pharmaceuticals operating margin
- Rhythm Pharmaceuticals dividend
- Rhythm Pharmaceuticals shares outstanding
- Rhythm Pharmaceuticals total debt
- Rhythm Pharmaceuticals cash on hand
- Rhythm Pharmaceuticals total assets
- Rhythm Pharmaceuticals return on equity (ROE)
- Rhythm Pharmaceuticals return on invested capital (ROIC)
Rhythm Pharmaceuticals (RYTM) overview: price, valuation and scorecardAll health care companies by market value
Rhythm Pharmaceuticals P/S ratio: questions and answers
What is Rhythm Pharmaceuticals's P/S ratio?
Rhythm Pharmaceuticals (RYTM) trades at 39.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 36.7×. That is 39.7% higher than the 26.2× of fiscal 2024.
Is Rhythm Pharmaceuticals's P/S ratio high or low compared with its own history?
Today's P/S ratio is higher than at 60% of the 5 fiscal year-ends on record; their median is 36.7×.
What are the highest and lowest P/S ratio figures on record for Rhythm Pharmaceuticals?
Across the 5 fiscal year-ends on record (2021–2025), the highest was 156.9× in fiscal 2021 and the lowest 26.2× in fiscal 2024.
How is Rhythm Pharmaceuticals's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Rhythm Pharmaceuticals (RYTM) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RYTM/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.